The promise of global cervical-cancer prevention

New England Journal of Medicine

Volumn 353, Issue 20, 2005, Pages 2101-2104

  Schiffman, Mark ^a   Castle, Philip E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; DIAGNOSTIC AGENT; HERPES VACCINE; VIRUS DNA;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DEVELOPING COUNTRY; HEALTH PROGRAM; HUMAN; IMMUNIZATION; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ADOLESCENT; ADULT; CRYOTHERAPY; DNA, VIRAL; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 27844510982     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp058171     Document Type: Review

References (3)

1. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
2. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
3. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.